About the Event

The fifth edition of Lung Update will cover the latest developments in the treatment of thoracic tumors in the fields of surgery, medical oncology, and radiation oncology, with an emphasis on multidisciplinary care.
Our main focus will be on the latest news from WCLC, ASCO, and ESMO 2026.

We will be joined by nationally renowned speakers, moderators, and panelists.

The activities will be divided into 4 blocks:
• Small-cell lung cancer/mesothelioma/thymic tumors: Transforming SCLC: Major breakthroughs driven by ADCs, BITEs, and chemotherapy;
• Non-small cell lung cancer in early-stage and advanced locoregional disease: Neoadjuvant therapy vs. perioperative therapy—do we have a new standard of care for localized disease?;
• Metastatic non-small cell lung cancer without a driver mutation: Another first-line option with bispecific antibodies, or a new standard of care? In the second-line setting, is docetaxel still the best option?;
• Advanced non-small cell lung cancer—with a driver mutation: Mutated EGFR: Intensification for everyone? MARIPOSA vs. FLAURA 2. Promising data in the second-line setting (ADCs, bispecific antibodies). How should treatment be sequenced?

The event will be held at the Grand Mercure Rayon.
You are our special guest—please join us!

Dr. Maikol Kurahashi and Dr. Elise Sanfelice
Program Coordinators

November 28, 2026, 8:00 a.m.

Event Timer

day(s)

hour(s)

minute(s)

second(s)

WHEN WILL THE EVENT TAKE PLACE?

DATE:

November 28, 2026

SCHEDULE:

8:30 a.m. to 12:55 p.m.

LOCATION:

Grand Mercure Rayon
Rua Visconde de Nácar, 1424 - Downtown, Curitiba - PR, 80410-201

TARGET AUDIENCE:

Clinical Oncologists; Pulmonologists; Thoracic Surgeons; Radiation Oncologists; Radiologists; Pathologists; and Resident Physicians

Confirmed Attendees

Schedule

8:30 a.m. – Breakfast – Meet the professor
8:50 a.m. – Welcome and opening remarks: Dr. Elise Sanfelice and Dr. Maikol Kurahashi

Session 1: Small Cell Lung Cancer/Mesothelioma/Thymic Tumors: Transforming SCLC: Breakthrough Results Driven by ADCs, BITEs, and Chemotherapy. | Moderator:

9:00 a.m. – New horizons in the management of rare thoracic neoplasms.
Speaker:
9:15 a.m. – Discussion
Discussants:

Session 2: Non-Small Cell Lung Cancer in Early-Stage and Advanced Locoregional Disease: Neoadjuvant Therapy vs. Perioperative Therapy—Is There a New Standard of Care for Localized Disease? | Moderator:

9:30 a.m. – What Changes for the Thoracic Surgeon with the Introduction of Immunotherapy in the Perioperative Setting.
Speaker:
09:45 – Has systemic therapy changed the paradigms for localized and locally advanced disease?
Speaker:
10:00 – KN-671: How does perioperative treatment transform the prognosis in different subgroups of resectable NSCLC?
Speaker:
10:20 – Discussion
Discussants:

10:35 – Coffee Break

10:55 – How should “unresectable” be defined? What is the standard of care for patients with advanced, inoperable locoregional disease?
Speaker:

Block 3: Metastatic non-small cell lung cancer without a driver mutation: Another first-line option with a bispecific antibody, or a new standard of care? Is docetaxel still the best option in the second line? | Moderator:

11:25 – How to decide on first-line treatment? Who should receive anti-CTLA-4 therapy? Will QT + bispecific antibodies become the new standard?
Speaker:
11:40 – Discussion
Discussants:

11:55 – What is the best strategy for patients with advanced NSCLC who do not have a driver mutation and are not eligible for chemotherapy?
Speaker:

Session 4: Advanced non-small cell lung cancer—with a driver mutation: EGFR mutation—intensification for all? MARIPOSA vs. FLAURA 2. Promising data in second-line treatment (ADCs, bispecific antibodies). How to proceed? | Moderator:

12:25 – From mutation to treatment decision: The impact of precision medicine on CPNPC in 2025.
Speaker:
12:40 – Discussion
Discussants:

12:55 – Closing Remarks: Dr. Elise Sanfelice and Dr. Maikol Kurahashi
Lunch will be served at the hotel restaurant